BioSight
Companies
ASTRAZENECA PLC logo

AZN

NYSECAMBRIDGE
ASTRAZENECA PLC

AstraZeneca PLC is a global biopharmaceutical company with a diversified pipeline spanning oncology, cardiovascular and renal medicine, respiratory and immunology, and rare disease. The company is advancing multiple drug modalities including antibody-drug conjugates (ADCs) such as AZD0516 for prostate cancer and sonesitatug vedotin for solid tumors, cell therapies like AZD0120 (a CD19/BCMA CAR-T in Phase II for multiple myeloma) and AZD0754 for prostate cancer, bispecific antibodies including volrustomig (a PD-1/CTLA-4 bispecific) in Phase III for renal cell carcinoma, and gene therapies such as ALXN2350 (an AAV therapy for BAG3-associated dilated cardiomyopathy in rare

$187.37+34.16%1Y
AZN · daily close · illustrative · 0 catalysts marked
$121$145$169$193$216Apr '25Aug '25Dec '25Apr '26
1Y high$208.451Y low$128.84range$79.61(62%)past catalysts

Pipeline256

(Osimertinib cohort, single-arm, open-label separate cohort)
Phase 3Non-Small Cell Lung Cancer
small-molecule
5-Fluorouracil
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
Abemaciclib
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Phase 2ER+ HER2- Advanced Breast Cancer
Phase 2High-grade Serous Ovarian Cancer (HGSOC)
Phase 3Breast Cancer, Early Breast Cancer
Phase 3Advanced Breast Cancer
small-molecule
abiraterone
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 2Metastatic Prostate Cancer
Phase 3Hormone-Sensitive Prostate Cancer
small-molecule
Abiraterone + Prednisolone/Prednisone
Phase 3Prostate Cancer
small-molecule
Abraxane + carboplatin
Phase 3Non-Small Cell Lung Cancer
small-molecule
Acalabrutinib
Phase 3Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 3Untreated Chronic Lymphocytic Leukemia
Phase 2Phase I: Relapsed or Refractory B-cell Malignancies
Phase 2Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
Phase 2Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Anastrozole
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 3Breast Cancer, Early Breast Cancer
Phase 3Advanced Breast Cancer
small-molecule
Androgen Deprivation Therapy (ADT)
Phase 3Prostate Cancer
small-molecule
Anifrolumab
Phase 3Lupus Nephritis
Phase 3Systemic Lupus Erythematosus
small-molecule
Apatinib
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
small-molecule
Atezolizumab
Phase 3Hepatocellular Carcinoma
small-molecule
AZD0120
Phase 3Relapsed Refractory Multiple Myeloma
Phase 2Lupus Erythematosus, Systemic
small-molecule
AZD0486
Phase 3Large B-cell Lymphoma
Phase 2B-cell Acute Lymphoblastic Leukemia (B-ALL)
small-molecule
AZD0780
Phase 3Cardiovascular Disease
Phase 3Heterozygous Familial Hypercholesterolaemia
Phase 2/3Dyslipidaemia
small-molecule
AZD0901
Phase 2Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Gastroesophageal Adenocarcinoma
small-molecule
AZD5335
Phase 3Epithelial Ovarian Cancer
Phase 2Ovarian Cancer
Phase 2Lung Adenocarcinoma
Phase 2Endometrial Cancer
small-molecule
AZD9291 80 mg/40 mg
Phase 3Stage IB-IIIA Non-small Cell Lung Carcinoma
small-molecule
AZD9833
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 2Advanced ER-Positive HER2-Negative Breast Cancer
small-molecule
Bacillus Calmette-Guerin (BCG)
Phase 3Non-muscle-invasive Bladder Cancer
small-molecule
Baxdrostat
Phase 3Primary Hyperaldosteronism
small-molecule
Baxdrostat and dapagliflozin
Phase 3Heart Failure
small-molecule
BCG
Phase 3Non-muscle-invasive Bladder Cancer
small-molecule
BDA MDI HFA 160/180 μg
Phase 3Asthma
small-molecule
BDA MDI HFO 160/180 μg
Phase 3Asthma
small-molecule
Benralizumab
Phase 3Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Phase 3Hypereosinophilia Syndrome (HES)
Phase 3Severe Eosinophilic Asthma
Phase 3Hypereosinophilic Syndrome
Phase 3Asthma
small-molecule
Bevacizumab
Phase 3Hepatocellular Carcinoma
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 2Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Phase 2Ovarian
Phase 2Breast
Phase 2SCLC
Phase 2Gastric Cancers
Phase 2Lung Adenocarcinoma
Phase 3Advanced Ovarian Cancer
Phase 2Metastatic Colorectal Cancer
small-molecule
BGF MDI 320/14.4/9.6 μg
Phase 3COPD (Chronic Obstructive Pulmonary Disease)
small-molecule
Bortezomib
Phase 3Relapsed Refractory Multiple Myeloma
small-molecule
BR
Phase 3Untreated Follicular Lymphoma
small-molecule
Camizestrant
Phase 2ER+ HER2- Advanced Breast Cancer
Phase 2High-grade Serous Ovarian Cancer (HGSOC)
Phase 2Ovarian Cancer
Phase 2Breast Cancer
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2Bladder Cancer
Phase 2Gastric Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Endometrial Cancer
Phase 2Small Cell Lung Cancer Only in Module 5
Phase 3Breast Cancer, Early Breast Cancer
Phase 3Advanced Breast Cancer
small-molecule
Capecitabine
Phase 3Breast Cancer
Phase 3Biliary Tract Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
Phase 3Advanced or Metastatic Breast Cancer
Phase 2Gastroesophageal Adenocarcinoma
small-molecule
Capivasertib
Phase 3Breast Cancer
Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Phase 3Prostate Cancer
Phase 2Triple Negative Breast Neoplasms
Phase 3Hormone-Sensitive Prostate Cancer
Phase 3Locally Advanced or Metastatic Breast Cancer
small-molecule
Carboplatin
Phase 3Breast Cancer
Phase 2Small Cell Lung Cancer
Phase 3Carcinoma
Phase 3Non-Small-Cell Lung
Phase 3Small Cell Lung Carcinoma Extensive Disease
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase 2Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Phase 2Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Bladder Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Lung Adenocarcinoma
Phase 3Unresectable Pleural Mesothelioma
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 3Endometrial Neoplasms
Phase 3Non-Small Cell Lung Cancer
small-molecule
Carboplatin + Gemcitabine
Phase 3Unresectable Locally Advanced Urothelial Cancer
Phase 3Metastatic Urothelial Cancer
small-molecule
Carboplatin/Paclitaxel
Phase 2Non-Small Cell Lung Cancer
Phase 3Advanced Ovarian Cancer
small-molecule
Carfilzomib
Phase 3Relapsed Refractory Multiple Myeloma
small-molecule
Casdatifan
Phase 3Advanced Clear Cell Renal Cell Carcinoma
small-molecule
Ceralasertib
Phase 2Non-Small Cell Lung Cancer
Phase 3Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Melanoma
small-molecule
Cetuximab
Phase 3Squamous Cell Carcinoma of the Head and Neck
small-molecule
Chlorambucil
Phase 3Untreated Chronic Lymphocytic Leukemia
small-molecule
Cisplatin
Phase 2Small Cell Lung Cancer
Phase 3Carcinoma
Phase 3Non-Small-Cell Lung
Phase 3Small Cell Lung Carcinoma Extensive Disease
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase 2Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Phase 2Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Phase 2Hepatocellular Carcinoma
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Unresectable Pleural Mesothelioma
Phase 3Muscle Invasive Bladder Cancer
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 3Urinary Bladder Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
Phase 3Non-Small Cell Lung Cancer
small-molecule
cisplatin + capecitabine
Phase 3Esophageal Squamous Cell Carcinoma
small-molecule
cisplatin + fluorouracil
Phase 3Esophageal Squamous Cell Carcinoma
small-molecule
Cisplatin + Gemcitabine
Phase 3Unresectable Locally Advanced Urothelial Cancer
Phase 3Metastatic Urothelial Cancer
small-molecule
Cisplatin/ Etoposide
Phase 3Non-Small Cell Lung Cancer
small-molecule
Cyclophosphamide
Phase 3Breast Cancer
Phase 3HER2-positive Early Breast Cancer
Phase 2Lupus Erythematosus, Systemic
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Dapagliflozin
Phase 3Chronic Kidney Disease With High Proteinuria
small-molecule
Daratumumab
Phase 3Relapsed Refractory Multiple Myeloma
small-molecule
Darolutamide
Phase 2Metastatic Prostate Cancer
Phase 3Metastatic Castration-Sensitive Prostate Cancer
small-molecule
Dato-DXd
Phase 3Breast Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Ovarian Cancer
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Colorectal Cancer
Phase 2Bladder Cancer
Phase 2Gastric Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Endometrial Cancer
Phase 2Small Cell Lung Cancer Only in Module 5
small-molecule
Datopotamab Deruxtecan
Phase 3Non-Small Cell Lung Cancer
Phase 2Triple Negative Breast Neoplasms
small-molecule
Datopotamab deruxtecan (Dato-DXd)
Phase 3Non-Small Cell Lung Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 2Advanced Solid Malignancies
Phase 2Breast Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Dexamethasone
Phase 3Relapsed Refractory Multiple Myeloma
small-molecule
Docetaxel
Phase 3Non-Small Cell Lung Cancer
Phase 3Prostate Cancer
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
Phase 3Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Endometrial Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
small-molecule
Domvanalimab
Phase 3Non-Small Cell Lung Cancer
small-molecule
Doxorubicin
Phase 3Endometrial Cancer
Phase 3Malignant Solid Tumour
Phase 3Breast Cancer
Phase 3HER2-positive Early Breast Cancer
Phase 3Urinary Bladder Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Durvalumab
Phase 3Hepatocellular Carcinoma
Phase 3Breast Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
Phase 3Small Cell Lung Carcinoma Extensive Disease
Phase 3Biliary Tract Neoplasms
Phase 3Biliary Tract Cancer
Phase 2Lung Cancer
Phase 3Gastrointestinal Neoplasms
Phase 3Esophagogastric Junction
Phase 3Esophageal Squamous Cell Carcinoma
Phase 3Papillary Renal Cell Carcinoma
Phase 2Triple Negative Breast Neoplasms
Phase 3Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Urinary Bladder Neoplasms
Phase 3Advanced Hepatocellular Carcinoma
Phase 3Non-muscle-invasive Bladder Cancer
Phase 2Locally Advanced or Metastatic Solid Tumours
Phase 3Muscle Invasive Bladder Cancer
Phase 3Endometrial Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
Phase 3Advanced Ovarian Cancer
Phase 2Melanoma
Phase 2Gastric Cancer
Phase 3Unresectable Locally Advanced Urothelial Cancer
Phase 3Metastatic Urothelial Cancer
Phase 2Breast Cancer
Phase 3Non-Small Cell Lung Cancer
small-molecule
Durvalumab (MEDI4736)
Phase 3Non-muscle-invasive Bladder Cancer
Phase 3Non Small Cell Lung Carcinoma NSCLC
small-molecule
Durvalumab (Regimen 1)
Phase 3Hepatocellular Carcinoma
small-molecule
Durvalumab (Regimen 2)
Phase 3Hepatocellular Carcinoma
small-molecule
Durvalumab + Chemotherapy phase
Phase 3Advanced or Recurrent Endometrial Cancer
small-molecule
Durvalumab + Olaparib phase
Phase 3Advanced or Recurrent Endometrial Cancer
small-molecule
Durvalumab +Tremelimumab
Phase 3Non Small Cell Lung Carcinoma NSCLC
small-molecule
Enfortumab Vedotin
Phase 3Muscle Invasive Bladder Cancer
small-molecule
Enzalutamide
Phase 2Metastatic Prostate Cancer
Phase 3Metastatic Castration-Sensitive Prostate Cancer
small-molecule
Epirubicin
Phase 3Breast Cancer
small-molecule
Eplontersen
Phase 3Transthyretin Amyloid Cardiomyopathy
small-molecule
Eribulin
Phase 3Breast Cancer
small-molecule
Eribulin
Phase 3Breast Cancer
small-molecule
Etoposide
Phase 2Small Cell Lung Cancer
Phase 3Small Cell Lung Carcinoma Extensive Disease
Phase 2Non-Small Cell Lung Cancer
small-molecule
Exemestane
Phase 3Breast Cancer, Early Breast Cancer
Phase 3Advanced Breast Cancer
small-molecule
FLOT chemotherapy
Phase 3Gastrointestinal Neoplasms
Phase 3Esophagogastric Junction
Phase 2Gastroesophageal Adenocarcinoma
small-molecule
Fulvestrant
Phase 3Breast Cancer
Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Phase 2Advanced ER-Positive HER2-Negative Breast Cancer
Phase 3Advanced Breast Cancer
Phase 3Locally Advanced or Metastatic Breast Cancer
small-molecule
Gemcitabine
Phase 3Breast Cancer
Phase 2Hepatocellular Carcinoma
Phase 2Biliary Tract Cancer
Phase 2Gastric Cancer
Phase 2Gastroesophageal Junction Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 3Urothelial Cancer
Phase 2Locally Advanced or Metastatic Solid Tumours
Phase 3Muscle Invasive Bladder Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 3Urinary Bladder Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
small-molecule
Gemcitabine + cisplatin + albumin-bound paclitaxel
Phase 3Biliary Tract Cancer
small-molecule
Gemcitabine + cisplatin + S-1
Phase 3Biliary Tract Cancer
small-molecule
Gemcitabine + oxaliplatin
Phase 3Biliary Tract Cancer
small-molecule
Gemcitabine + S-1
Phase 3Biliary Tract Cancer
small-molecule
Gemcitabine monotherapy
Phase 3Biliary Tract Cancer
small-molecule
Gemcitabine/Cisplatin
Phase 3Biliary Tract Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Gemcitabine+carboplatin
Phase 3Biliary Tract Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
GFF MDI 14.4/9.6 μg
Phase 3COPD (Chronic Obstructive Pulmonary Disease)
small-molecule
Ipilimumab
Phase 3Unresectable Pleural Mesothelioma
Phase 3Advanced Clear Cell Renal Cell Carcinoma
small-molecule
Irinotecan
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
Letrozole
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 3Breast Cancer, Early Breast Cancer
Phase 3Advanced Breast Cancer
small-molecule
Leucovorin
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
Luteinizing hormone-releasing hormone (LHRH) agonist
Phase 3ER-Positive HER2-Negative Breast Cancer
small-molecule
Medi-546
Phase 3Systemic Lupus Erythematosus
small-molecule
MEDI4736 (Durvalumab)
Phase 3Urothelial Cancer
Phase 3Non Small Cell Lung Carcinoma NSCLC
small-molecule
MEDI4736 (Durvalumab)+Tremelimumab
Phase 3Non Small Cell Lung Carcinoma NSCLC
small-molecule
Mepolizumab
Phase 3Eosinophilic Granulomatous Vasculitis
small-molecule
Methotrexate
Phase 3Urinary Bladder Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
small-molecule
Mirvetuximab Soravtansine (MIRV)
Phase 3Epithelial Ovarian Cancer
small-molecule
Monalizumab
Phase 3Squamous Cell Carcinoma of the Head and Neck
Phase 2Non-Small Cell Lung Cancer
small-molecule
Nab-paclitaxel
Phase 3Breast Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 2Locally Advanced or Metastatic Solid Tumours
small-molecule
Nexium 10mg
Phase 3Erosive Esophagitis
small-molecule
Nexium 20mg
Phase 3Erosive Esophagitis
small-molecule
Nivolumab
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
Phase 3Unresectable Pleural Mesothelioma
Phase 3Advanced Clear Cell Renal Cell Carcinoma
small-molecule
Obinutuzumab
Phase 3Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
small-molecule
Olaparib
Phase 3Ovarian Cancer
Phase 3Breast Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian
Phase 2Breast
Phase 2SCLC
Phase 2Gastric Cancers
Phase 2Urinary Bladder Neoplasms
Phase 3Endometrial Neoplasms
Phase 3Advanced Ovarian Cancer
small-molecule
Olaparib 300mg tablets
Phase 3Newly Diagnosed
Phase 3Advanced Ovarian Cancer
Phase 3FIGO Stage III-IV
Phase 3BRCA Mutation
Phase 3Complete Response
Phase 3Partial Response
Phase 3First Line Platinum Chemotherapy
Phase 3Platinum Sensitive
Phase 3BRCA Mutated
Phase 3Relapsed Ovarian Cancer
Phase 3Following Complete or Partial Response to Platinum Based Chemotherapy
small-molecule
Open-label AZD9291 80 mg/40 mg
Phase 3Stage IB-IIIA Non-small Cell Lung Carcinoma
small-molecule
Osimertinib
Phase 3Non-Small Cell Lung Cancer
Phase 3Carcinoma
Phase 3Non-Small-Cell Lung
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 3Cancer
Phase 2Lung Cancer
small-molecule
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Phase 3Non-Small Cell Lung Cancer
small-molecule
Osimertinib 80mg/40mg
Phase 3Non Small Cell Lung Cancer (Stage III)
small-molecule
Oxaliplatin
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Gastric Cancer
Phase 3Esophageal Cancer
small-molecule
Paclitaxel
Phase 3Breast Cancer
Phase 3Endometrial Cancer
Phase 3Malignant Solid Tumour
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase 2Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Phase 2Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Phase 3Epithelial Ovarian Cancer
Phase 2Ovarian Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Colorectal Cancer
Phase 2Bladder Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Small Cell Lung Cancer Only in Module 5
Phase 2Triple Negative Breast Neoplasms
Phase 3HER2-positive Early Breast Cancer
Phase 3Endometrial Neoplasms
Phase 2Breast Cancer
Phase 3Non-Small Cell Lung Cancer
small-molecule
Paclitaxel + carboplatin
Phase 3Non Small Cell Lung Carcinoma NSCLC
small-molecule
Palbociclib
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Phase 2ER+ HER2- Advanced Breast Cancer
Phase 2High-grade Serous Ovarian Cancer (HGSOC)
Phase 3Advanced Breast Cancer
small-molecule
Pegylated G-CSF
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
small-molecule
Pegylated liposomal Doxorubicin (PLD)
Phase 3Epithelial Ovarian Cancer
small-molecule
Pembrolizumab
Phase 3Breast Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Non-Small Cell Lung Cancer
Phase 3Endometrial Cancer
Phase 2Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2Hodgkin Lymphoma
Phase 2Peripheral T-cell Lymphoma (PTCL)
Phase 2PTCL-NOS
Phase 2ALCL
Phase 2AITL
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 2Gastric Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Pemetrexed
Phase 3Carcinoma
Phase 3Non-Small-Cell Lung
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 3Unresectable Pleural Mesothelioma
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 3Non-Small Cell Lung Cancer
small-molecule
Pemetrexed/Carboplatin
Phase 3Non-Small Cell Lung Cancer
small-molecule
Pemetrexed/Cisplatin
Phase 3Non-Small Cell Lung Cancer
small-molecule
Pertuzumab
Phase 3Breast Cancer; HER2-positive; Metastatic
Phase 3HER2-positive Early Breast Cancer
Phase 3Breast Cancer
Phase 2Breast Cancer
small-molecule
Pomalidomide
Phase 3Relapsed Refractory Multiple Myeloma
small-molecule
Puxitatug Samrotecan
Phase 3Endometrial Cancer
Phase 3Malignant Solid Tumour
small-molecule
R-CHOP
Phase 3Untreated Follicular Lymphoma
small-molecule
R-CVP
Phase 3Untreated Follicular Lymphoma
small-molecule
R-mini-CHOP
Phase 3Large B-cell Lymphoma
small-molecule
Ramucirumab+ paclitaxel
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
small-molecule
Ribociclib
Phase 3ER-Positive HER2-Negative Breast Cancer
Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Phase 2ER+ HER2- Advanced Breast Cancer
Phase 2High-grade Serous Ovarian Cancer (HGSOC)
Phase 3Advanced Breast Cancer
small-molecule
Rilvegostomig
Phase 3Biliary Tract Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 2Hepatocellular Carcinoma
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
Phase 2Melanoma
Phase 2Squamous Cell Carcinoma (Skin)
Phase 2Renal Cell Carcinoma
Phase 2Merkel Cell Carcinoma
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 2Gastric Cancer/Gastroesophageal Junction Cancer
Phase 2High Grade Serous Ovarian Carcinoma
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 2Gastroesophageal Adenocarcinoma
Phase 2Breast Cancer
small-molecule
Rituximab
Phase 2Diffuse Large B-Cell Lymphoma
Phase 3Untreated Chronic Lymphocytic Leukemia
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
S-1 [Tegafur/Oteracil/gimeracil]
Phase 3Biliary Tract Cancer
small-molecule
Saruparib
Phase 2Solid Tumours
Phase 3Prostate Cancer
Phase 3Metastatic Castration-Sensitive Prostate Cancer
small-molecule
Saruparib (AZD5305)
Phase 2Ovarian Cancer
Phase 2Lung Adenocarcinoma
Phase 2Endometrial Cancer
Phase 3Advanced Breast Cancer
small-molecule
Savolitinib
Phase 3Carcinoma
Phase 3Carcinoma, Renal Cell
Phase 3Kidney Neoplasms
Phase 3Urologic Neoplasms
Phase 3Kidney Diseases
Phase 3Neoplasms by Site
Phase 3Enzyme Inhibitors
Phase 3Protein Kinase Inhibitors
Phase 3Non-Small-Cell Lung
Phase 2Lung Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 3Papillary Renal Cell Carcinoma
small-molecule
Selumetinib
Phase 3Neurofibromatosis 1
Phase 3Plexiform Neurofibroma (PN)
Phase 2Non-Small Cell Lung Cancer
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
small-molecule
Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)
Phase 3Hyperkalaemia
small-molecule
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level
Phase 3Hyperkalaemia
small-molecule
Sonesitatug vedotin
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
small-molecule
Sorafenib
Phase 3Hepatocellular Carcinoma
small-molecule
Sunitinib
Phase 3Carcinoma
Phase 3Carcinoma, Renal Cell
Phase 3Kidney Neoplasms
Phase 3Urologic Neoplasms
Phase 3Kidney Diseases
Phase 3Neoplasms by Site
Phase 3Enzyme Inhibitors
Phase 3Protein Kinase Inhibitors
Phase 3Papillary Renal Cell Carcinoma
small-molecule
Surovatamig
Phase 3Untreated Follicular Lymphoma
Phase 2Follicular Lymphoma (FL)
Phase 2Large B-Cell Lymphoma (LBCL)
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Tamoxifen
Phase 3Breast Cancer, Early Breast Cancer
small-molecule
TAS-102
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Cancer
small-molecule
Taxane
Phase 3Breast Cancer; HER2-positive; Metastatic
small-molecule
Tezepelumab
Phase 3Severe Asthma
Phase 3Asthma
Phase 3Eosinophilic Esophagitis
Phase 3Chronic Obstructive Pulmonary Disease (COPD)
small-molecule
Topotecan
Phase 3Epithelial Ovarian Cancer
small-molecule
Tozorakimab
Phase 2Chronic Obstructive Pulmonary Disease (COPD)
Phase 3Viral Lung Infection and Acute Respiratory Failure
Phase 2Asthma
small-molecule
Trastuzumab
Phase 3Breast Cancer; HER2-positive; Metastatic
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3HER2-positive Early Breast Cancer
Phase 2Gastric Cancer
Phase 3Breast Cancer
small-molecule
Trastuzumab deruxtecan
Phase 2Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
Phase 3Breast Cancer; HER2-positive; Metastatic
Phase 3Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
Phase 2Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 3Breast Cancer
Phase 3Biliary Tract Cancer
Phase 3HER2-positive Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 2Triple Negative Breast Neoplasms
Phase 3Endometrial Cancer
Phase 3Advanced or Metastatic Breast Cancer
Phase 3HER2-positive Early Breast Cancer
Phase 2HER2-mutant Non-Small Cell Lung Cancer
Phase 2Gastric Cancer
Phase 2Breast Cancer
small-molecule
Tremelimumab
Phase 3Small Cell Lung Carcinoma Extensive Disease
Phase 3Small Cell Lung Cancer
Phase 3Urothelial Cancer
Phase 3Advanced Hepatocellular Carcinoma
Phase 3Non-Small Cell Lung Cancer
Phase 3Muscle Invasive Bladder Cancer
Phase 2Hepatocellular Carcinoma
Phase 3Unresectable Locally Advanced Urothelial Cancer
Phase 3Metastatic Urothelial Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Tremelimumab (Regimen 1)
Phase 3Hepatocellular Carcinoma
small-molecule
Tremelimumab (Regimen 2)
Phase 3Hepatocellular Carcinoma
small-molecule
UFT
Phase 3Non-Small Cell Lung Cancer
small-molecule
Venetoclax
Phase 3Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2Mantle Cell Lymphoma (MCL)
small-molecule
Vinblastine
Phase 3Urinary Bladder Neoplasms
Phase 3Immune Checkpoint Inhibitors
Phase 3Methotrexate
Phase 3Vinblastine
Phase 3Doxorubicin
Phase 3Cisplatin
Phase 3Gemcitabine
small-molecule
Vinorelbine
Phase 3Non-Small Cell Lung Cancer
Phase 3Breast Cancer
small-molecule
Volrustomig
Phase 2Non-Small Cell Lung Cancer
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
Phase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase 2Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Phase 2Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Phase 2Hepatocellular Carcinoma
Phase 3Metastatic Non-small Cell Lung Cancer
Phase 3Locally Advanced Cervical Cancer
Phase 3Unresectable Pleural Mesothelioma
Phase 3Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Metastatic Colorectal Cancer
Phase 3Advanced Clear Cell Renal Cell Carcinoma
small-molecule
Zibotentan/Dapagliflozin
Phase 3Chronic Kidney Disease With High Proteinuria
small-molecule
Zolbetuximab
Phase 3Gastric Cancer
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Esophageal Cancer
small-molecule
Rosuvastatin Dose 1
Phase 2/3Dyslipidaemia
small-molecule
Rosuvastatin dose 2
Phase 2/3Dyslipidaemia
small-molecule
[11C]AZ1419 3391
Phase 2Advanced Solid Malignancies
small-molecule
5-Fluorouracil (5-FU)
Phase 2Gastroesophageal Adenocarcinoma
small-molecule
5-FU
Phase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase 2Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Phase 2Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Phase 2Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
small-molecule
Acalabrutinib + R-CHOP standard of care
Phase 2Mantle-cell Lymphoma
small-molecule
Acalabrutinib combination with Rituximab
Phase 2Mantle-cell Lymphoma
small-molecule
Acalabrutinib monotherapy
Phase 2Mantle-cell Lymphoma
small-molecule
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Phase 2Metastatic Triple Negative Breast Cancer
small-molecule
Administation of ceralasertib in combination with durvalumab
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Administration of ceralasertib
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Administration of ceralasertib and durvalumab
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Administration of ceralasertib and olaparib
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Administration of ceralasertib in combination with olaparib
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Administration of ceralasertib monotherapy
Phase 2Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
small-molecule
Alectinib
Phase 2Non-Small Cell Lung Cancer
small-molecule
Amivantamab
Phase 2Non-Small Cell Lung Cancer
small-molecule
Apalutamide
Phase 2Metastatic Prostate Cancer
small-molecule
AZD0171
Phase 2Non-Small Cell Lung Cancer
Phase 2Locally Advanced or Metastatic Solid Tumours
small-molecule
AZD0292
Phase 2Bronchiectasis With Pseudomonas Aeruginosa Colonization
small-molecule
AZD0305
Phase 2Multiple Myeloma
small-molecule
AZD0516
Phase 2Metastatic Prostate Cancer
small-molecule
AZD0754
Phase 2Metastatic Prostate Cancer
small-molecule
AZD1163
Phase 2Rheumatoid Arthritis
small-molecule
AZD2287
Phase 2Metastatic Prostate Cancer
small-molecule
AZD2811
Phase 2Small Cell Lung Cancer
small-molecule
AZD2936
Phase 2Non Small Cell Lung Carcinoma
small-molecule
AZD3470
Phase 2Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2Hodgkin Lymphoma
Phase 2Peripheral T-cell Lymphoma (PTCL)
Phase 2PTCL-NOS
Phase 2ALCL
Phase 2AITL
Phase 2Advanced Solid Tumors That Are MTAP Deficient
small-molecule
AZD3632
Phase 2Acute Lymphoblastic Leukaemia
Phase 2Acute Myeloid Leukaemia
Phase 2Higher-risk Myelodysplastic Syndromes
small-molecule
AZD4117
Phase 2Influenza A
small-molecule
AZD4144
Phase 2Sepsis
Phase 2Acute Kidney Injury
small-molecule
AZD4360
Phase 2Gastric Cancer
Phase 2Gastroesophageal Junction Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
AZD4512
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
AZD4956
Phase 2Solid Tumours
small-molecule
AZD5148
Phase 2Clostridioides Difficile Infection
small-molecule
AZD5305
Phase 2Metastatic Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Breast Cancer
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2Bladder Cancer
Phase 2Gastric Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Endometrial Cancer
Phase 2Small Cell Lung Cancer Only in Module 5
small-molecule
AZD5315
Phase 2Influenza A
small-molecule
AZD5492
Phase 2B-cell Malignancies
small-molecule
AZD5851
Phase 2Hepatocellular Carcinoma
small-molecule
AZD5863
Phase 2Gastric Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Esophageal Adenocarcinoma
Phase 2Gastroesophageal Junction Cancer
small-molecule
AZD6234
Phase 2Obesity or Overweight
Phase 2Obesity/Overweight
Phase 2Endocrinology
Phase 2Diabetes, Type II
Phase 2Obesity
small-molecule
AZD6234 in combination with AZD9550
Phase 2Obesity/Overweight
small-molecule
AZD6621
Phase 2Prostate Cancer
small-molecule
AZD6750
Phase 2Melanoma
Phase 2Non-Small Cell Lung Cancer
Phase 2Squamous Cell Carcinoma (Skin)
Phase 2Renal Cell Carcinoma
Phase 2Merkel Cell Carcinoma
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 2Gastric Cancer/Gastroesophageal Junction Cancer
Phase 2High Grade Serous Ovarian Carcinoma
Phase 2Breast Cancer
small-molecule
AZD6793
Phase 2Chronic Obstructive Pulmonary Disease (COPD)
small-molecule
AZD7760
Phase 2Staphylococcus Aureus
small-molecule
AZD7789
Phase 2Gastric Cancer
Phase 2Gastroesophageal Junction Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
AZD7798
Phase 2Moderate to Severe Crohn's Disease
Phase 2Crohn's Disease
small-molecule
AZD8205
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8205 and AZD2936 (Rilvegostomig)
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8205 and AZD5305 (saruparib)
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8205 in combination with AZD9574
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Phase 2Breast Cancer
Phase 2Biliary Tract Carcinoma
Phase 2Ovarian Cancer
Phase 2Endometrial Cancer
Phase 2Squamous Non-Small Cell Lung Cancer
small-molecule
AZD8421
Phase 2ER+ HER2- Advanced Breast Cancer
Phase 2High-grade Serous Ovarian Cancer (HGSOC)
small-molecule
AZD9550
Phase 2Obesity or Overweight
Phase 2Obesity
Phase 2Obesity/Overweight
small-molecule
AZD9550 and AZD6234
Phase 2Obesity
small-molecule
AZD9574
Phase 2Advanced Solid Malignancies
Phase 2Ovarian Cancer
Phase 2Lung Adenocarcinoma
Phase 2Endometrial Cancer
Phase 2Metastatic Prostate Cancer
small-molecule
AZD9793 Intravenous (IV) monotherapy
Phase 2Hepatocellular Carcinoma
small-molecule
AZD9793 Subcutaneous (SC) monotherapy
Phase 2Hepatocellular Carcinoma
small-molecule
AZD9829
Phase 2Hematological Malignancies
small-molecule
Baxdrostat/dapagliflozin
Phase 2Chronic Kidney Disease and Hypertension
small-molecule
Cediranib
Phase 2Non-Small Cell Lung Cancer
small-molecule
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Phase 2Metastatic Triple Negative Breast Cancer
small-molecule
Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
Phase 2Lung Cancer
small-molecule
Danvatirsen
Phase 2Non-Small Cell Lung Cancer
small-molecule
Drug: carboplatin
Phase 2Ovarian Cancer
small-molecule
Durvalumab / Tremelimumab Combination Therapy
Phase 2Pediatric Cancer
Phase 2Solid Tumor Pediatric
Phase 2Hematological Malignancies
small-molecule
Fludarabine
Phase 2Lupus Erythematosus, Systemic
small-molecule
Fluorouracil (5-FU)
Phase 2Gastric Cancer
small-molecule
FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Phase 2Metastatic Colorectal Cancer
small-molecule
FOLFOX
Phase 2Gastric Cancer
small-molecule
Gefitinib
Phase 2Non-Small Cell Lung Cancer
small-molecule
l-leucovorin
Phase 2Gastric Cancer
Phase 2Gastroesophageal Junction Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
Lenvatinib
Phase 2Hepatocellular Carcinoma
Phase 2Biliary Tract Cancer
small-molecule
MEDI4736
Phase 2Ovarian
Phase 2Breast
Phase 2SCLC
Phase 2Gastric Cancers
small-molecule
Nab-paclitaxel+carboplatin
Phase 2Non-Small Cell Lung Cancer
small-molecule
Nanoliposomal Irinotecan
Phase 2Gastric Cancer
Phase 2Gastroesophageal Junction Cancer
Phase 2Biliary Tract Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
small-molecule
Necitumumab
Phase 2Non-Small Cell Lung Cancer
small-molecule
Neoadjuvant Olaparib monotherapy group
Phase 2Breast Cancer
small-molecule
Olaparib Continuous (28-Day cycle) 300 mg BD.
Phase 2Metastatic Triple Negative Breast Cancer
small-molecule
Oleclumab
Phase 2Non-Small Cell Lung Cancer
Phase 2Triple Negative Breast Neoplasms
small-molecule
Osimertinib + Savolitinib
Phase 2Non-Small Cell Lung Cancer
small-molecule
Osimertinib 80 mg/40 mg
Phase 2Stage II-IIIB Non-small Cell Lung Carcinoma
small-molecule
Plocebo
Phase 2Obesity/Overweight
small-molecule
Posaconazole
Phase 2Acute Lymphoblastic Leukaemia
Phase 2Acute Myeloid Leukaemia
Phase 2Higher-risk Myelodysplastic Syndromes
small-molecule
Prednisone (or equivalent)
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Prednisone/ prednisolone
Phase 2Endometrial Cancer
Phase 2Gastric Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Ovarian Cancer
Phase 2Colorectal Cancer
Phase 2Urothelial Cancer
Phase 2Biliary Tract Cancer
small-molecule
Radiation
Phase 2Lung Cancer
small-molecule
Ramucirumab
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Rosuvastatin
Phase 2Dyslipidaemia
small-molecule
Selpercatinib
Phase 2Non-Small Cell Lung Cancer
small-molecule
Selumetinib capsule formulation
Phase 2Neurofibromatosis Type 1
small-molecule
Selumetinib granule formulation
Phase 2Neurofibromatosis Type 1
small-molecule
T- Dxd
Phase 2Ovarian Cancer
Phase 2Breast Cancer
Phase 2Pancreatic Cancer
Phase 2Prostate Cancer
Phase 2Additional Indications Below for Module 4 and 5
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2Bladder Cancer
Phase 2Gastric Cancer
Phase 2Biliary Cancer
Phase 2Cervical Cancer
Phase 2Endometrial Cancer
Phase 2Small Cell Lung Cancer Only in Module 5
small-molecule
Temozolomide (TMZ)
Phase 2Advanced Solid Malignancies
small-molecule
Trastuzumab Deruxtecan (T-DXd)
Phase 2Advanced Solid Malignancies
Phase 2Gastroesophageal Adenocarcinoma
small-molecule
Tucatinib
Phase 2Breast Cancer
small-molecule
Vincristine
Phase 2Chronic Lymphocytic Leukaemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Large B-cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
small-molecule
Vistusertib
Phase 2Non-Small Cell Lung Cancer
small-molecule
XELOX
Phase 2Gastric Cancer
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar